Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
09 2019
Historique:
received: 12 02 2019
accepted: 15 05 2019
pubmed: 17 7 2019
medline: 20 8 2020
entrez: 17 7 2019
Statut: ppublish

Résumé

Moxifloxacin is a widely used fluoroquinolone for the treatment of complicated intra-abdominal infections. We applied physiologically-based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) modeling to support dose selection in pediatric patients. We scaled an existing adult PBPK model to children based on prior physiological knowledge. The resulting model proposed an age-dependent dosing regimen that was tested in a phase I study. Refined doses were then tested in a phase III study. A popPK analysis of all clinical pediatric data confirmed the PBPK predictions, including the proposed dosing schedule in children, and supported pharmacokinetics-related safety/efficacy questions. The pediatric PBPK model adequately predicted the doses necessary to achieve antimicrobial efficacy while maintaining safety in the phase I and III pediatric studies. Altogether, this study retroactively demonstrated the robustness and utility of modeling to support dose finding and confirmation in pediatric drug development for moxifloxacin.

Identifiants

pubmed: 31310051
doi: 10.1002/psp4.12446
pmc: PMC6765696
doi:

Substances chimiques

Anti-Bacterial Agents 0
Moxifloxacin U188XYD42P

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

654-663

Informations de copyright

© 2019 Bayer AG, Leverkusen Germany CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

BMJ. 2000 Jan 8;320(7227):79-82
pubmed: 10625257
Ann Emerg Med. 2000 Jul;36(1):39-51
pubmed: 10874234
Arch Dis Child. 2000 Dec;83(6):498-501
pubmed: 11087285
AAPS PharmSci. 2000;2(1):E3
pubmed: 11741219
Pharm Res. 2004 May;21(5):785-92
pubmed: 15180335
Br J Clin Pharmacol. 2005 May;59(5):536-41
pubmed: 15842551
AAPS J. 2005 Oct 07;7(3):E544-59
pubmed: 16353932
Infection. 2005 Dec;33 Suppl 2:29-35
pubmed: 16518709
Clin Pharmacokinet. 2006;45(7):683-704
pubmed: 16802850
Ann Surg. 2006 Aug;244(2):204-11
pubmed: 16858182
Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):159-68
pubmed: 16922658
Clin Pharmacokinet. 2006;45(9):931-56
pubmed: 16928154
Clin Pharmacokinet. 2006;45(10):1013-34
pubmed: 16984214
Antimicrob Agents Chemother. 2008 Mar;52(3):852-7
pubmed: 18070980
Clin Pharmacokinet. 2009;48(3):181-7
pubmed: 19385711
J Chemother. 2009 Apr;21(2):170-80
pubmed: 19423470
Int J Antimicrob Agents. 2009 Nov;34(5):439-45
pubmed: 19692210
Clin Infect Dis. 2010 Jan 15;50(2):133-64
pubmed: 20034345
Paediatr Anaesth. 2011 Mar;21(3):206-13
pubmed: 21129100
Clin Pharmacol Ther. 2011 Feb;89(2):259-67
pubmed: 21191381
J Clin Pharmacol. 2011 Aug;51(8):1152-62
pubmed: 21228407
AAPS J. 2011 Jun;13(2):143-51
pubmed: 21302010
Pediatrics. 2011 Nov;128(5):e1242-9
pubmed: 22025597
Clin Pharmacol Ther. 2012 May;91(5):926-31
pubmed: 22472993
Drugs. 2012 Apr 16;72(6):e17-32
pubmed: 22480338
Int J Antimicrob Agents. 2013 Jan;41(1):57-64
pubmed: 23153963
J Antimicrob Chemother. 2013 Jun;68(6):1331-7
pubmed: 23463212
CPT Pharmacometrics Syst Pharmacol. 2013 Jul 03;2:e51
pubmed: 23836283
Clin Pharmacokinet. 2014 Jan;53(1):89-102
pubmed: 23912563
Adv Drug Deliv Rev. 2014 Jun;73:2-13
pubmed: 24556465
J Infect Chemother. 2014 Oct;20(10):621-6
pubmed: 25000831
CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):226-30
pubmed: 26225246
Pediatr Infect Dis J. 2018 Aug;37(8):e207-e213
pubmed: 29356761
J Clin Pharmacol. 2019 May;59(5):654-667
pubmed: 30681729
J Pharmacokinet Biopharm. 1977 Dec;5(6):625-53
pubmed: 599411
Clin Pharmacol Ther. 1997 Mar;61(3):275-91
pubmed: 9084453
Pharm Res. 1998 Sep;15(9):1463-8
pubmed: 9755901

Auteurs

Stefan Willmann (S)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals Bayer AG, Wuppertal, Germany.

Matthias Frei (M)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals Bayer AG, Berlin, Germany.

Gabriele Sutter (G)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals Bayer AG, Berlin, Germany.

Katrin Coboeken (K)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals Bayer AG, Leverkusen, Germany.

Thomas Wendl (T)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals Bayer AG, Leverkusen, Germany.

Thomas Eissing (T)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals Bayer AG, Leverkusen, Germany.

Jörg Lippert (J)

Clinical Pharmacometrics, Research & Development, Pharmaceuticals Bayer AG, Wuppertal, Germany.

Heino Stass (H)

Clinical Pharmacology, Research & Development, Pharmaceuticals Bayer AG, Wuppertal, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH